{"nctId":"NCT00947765","briefTitle":"A Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis","startDateStruct":{"date":"2007-01"},"conditions":["Tennis Elbow","Epicondylitis, Lateral Humeral"],"count":60,"armGroups":[{"label":"Autologous blood injection group","type":"EXPERIMENTAL","interventionNames":["Biological: Autologous blood injection"]},{"label":"Local corticosteroid injection group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Local corticosteroid injection"]}],"interventions":[{"name":"Autologous blood injection","otherNames":["autologous blood drawn from peripheral vein."]},{"name":"Local corticosteroid injection","otherNames":["Methyl prednisolone acetate 80mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Cases of lateral epicondylitis.\n2. Men and women above fifteen years of age.\n\nExclusion Criteria:\n\n1. Patients receiving steroid injections within three months before blood injection.\n2. A history of substantial trauma.\n3. Previously treated by surgery for lateral epicondylitis.\n4. Other causes of elbow pain such as osteochondritis dessecans of capitellum, lateral compartment arthrosis, varus instability, radial head arthritis, posterior interosseous nerve syndrome, cervical disc syndrome, synovitis of radiohumeral joint, cervical radiculopathy, fibromyalgia, osteoarthritis of elbow, carpel tunnel syndrome.","healthyVolunteers":true,"sex":"ALL","minimumAge":"15 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain (at 1 Week): Visual Analogue Scale(0 to 10)","description":"VISUAL ANALOGUE SCALE:\n\nPain of the participants will be assessed by most widely used and accepted \"visual analogue scale\". It consists of a 10 centimeter line marked at one end with \"no pain\" and at other end with \"worst pain ever\". Participant is asked to indicate where on the line he or she rates the pain on the day of presentation, 1, 4, 12weeks and 6 month of follow-ups. Numerical valve is then given to it simply by measuring length between \"no pain\" to patients mark.\n\nNo pain\\_\\_\\_\\_1\\_\\_\\_2\\_\\_\\_3\\_\\_\\_4\\_\\_\\_5\\_\\_\\_6\\_\\_\\_7\\_\\_\\_8\\_\\_\\_9\\_\\_\\_10 worst pain ever.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.166","spread":"1.9312"},{"groupId":"OG001","value":"4.5","spread":"1.8708"}]}]}]},{"type":"PRIMARY","title":"Pain(at 1 Week): Nirschl Staging (0 to 7)","description":"NIRSCHL STAGING:\n\nphase1: mild pain with exercise; resolves within 24 hours phase2: pain after exercise; exceeds 48 hours phase3: pain with exercise; does not alter activity phase4: pain with exercise; alters activity phase5: pain with heavy activities of daily living phase6: pain with light activities of daily living; intermittent pain at rest phase7: constant pain at rest; disrupts sleeps\n\nNo pain\\_\\_\\_\\_\\_\\_1 \\_\\_\\_\\_\\_\\_ 2\\_\\_\\_\\_\\_\\_ 3\\_\\_\\_\\_\\_\\_\\_4\\_\\_\\_\\_\\_\\_ 5\\_\\_\\_\\_\\_\\_ 6 \\_\\_\\_\\_\\_ 7 worst pain","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"1.4703"},{"groupId":"OG001","value":"3.06","spread":"1.3629"}]}]}]},{"type":"PRIMARY","title":"Pain(at 4 Weeks): Visual Analogue Scale","description":"VISUAL ANALOGUE SCALE:\n\nPain of the participants will be assessed by most widely used and accepted \"visual analogue scale\". It consists of a 10 centimeter line marked at one end with \"no pain\" and at other end with \"worst pain ever\". Participant is asked to indicate where on the line he or she rates the pain on the day of presentation, 1, 4, 12weeks and 6 month of follow-ups. Numerical valve is then given to it simply by measuring length between \"no pain\" to patients mark.\n\nNo pain\\_\\_\\_\\_1 \\_\\_\\_ 2 \\_\\_\\_ 3 \\_\\_\\_ 4 \\_\\_\\_ 5 \\_\\_\\_ 6 \\_\\_\\_ 7 \\_\\_\\_ 8 \\_\\_\\_ 9 \\_\\_\\_ 10 worst pain ever.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.369"},{"groupId":"OG001","value":"1.533","spread":"2.315"}]}]}]},{"type":"PRIMARY","title":"Pain(at 4 Weeks): Nirschl Staging","description":"NIRSCHL STAGING:\n\nphase1: mild pain with exercise; resolves within 24 hours phase2: pain after exercise; exceeds 48 hours phase3: pain with exercise; does not alter activity phase4: pain with exercise; alters activity phase5: pain with heavy activities of daily living phase6: pain with light activities of daily living; intermittent pain at rest phase7: constant pain at rest; disrupts sleeps\n\nNo pain\\_\\_\\_\\_\\_\\_1 \\_\\_\\_\\_\\_\\_ 2\\_\\_\\_\\_\\_\\_ 3\\_\\_\\_\\_\\_\\_\\_4\\_\\_\\_\\_\\_\\_ 5\\_\\_\\_\\_\\_\\_ 6 \\_\\_\\_\\_\\_ 7 worst pain","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.6484"},{"groupId":"OG001","value":"1.03","spread":"1.5862"}]}]}]},{"type":"PRIMARY","title":"Pain(at 12 Weeks): Visual Analogue Scale","description":"VISUAL ANALOGUE SCALE:\n\nPain of the participants will be assessed by most widely used and accepted \"visual analogue scale\". It consists of a 10 centimeter line marked at one end with \"no pain\" and at other end with \"worst pain ever\". Participant is asked to indicate where on the line he or she rates the pain on the day of presentation, 1, 4, 12weeks and 6 month of follow-ups. Numerical valve is then given to it simply by measuring length between \"no pain\" to patients mark.\n\nNo pain\\_\\_\\_\\_1 \\_\\_\\_ 2 \\_\\_\\_ 3 \\_\\_\\_ 4 \\_\\_\\_ 5 \\_\\_\\_ 6 \\_\\_\\_ 7 \\_\\_\\_ 8 \\_\\_\\_ 9 \\_\\_\\_ 10 worst pain ever.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.9046"},{"groupId":"OG001","value":"1.5","spread":"1.8147"}]}]}]},{"type":"PRIMARY","title":"Pain(at 12 Weeks): Nirschl Staging","description":"NIRSCHL STAGING:\n\nphase1: mild pain with exercise; resolves within 24 hours phase2: pain after exercise; exceeds 48 hours phase3: pain with exercise; does not alter activity phase4: pain with exercise; alters activity phase5: pain with heavy activities of daily living phase6: pain with light activities of daily living; intermittent pain at rest phase7: constant pain at rest; disrupts sleeps\n\nNo pain\\_\\_\\_\\_\\_\\_1 \\_\\_\\_\\_\\_\\_ 2\\_\\_\\_\\_\\_\\_ 3\\_\\_\\_\\_\\_\\_\\_4\\_\\_\\_\\_\\_\\_ 5\\_\\_\\_\\_\\_\\_ 6 \\_\\_\\_\\_\\_ 7 worst pain","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.433","spread":"1.278"},{"groupId":"OG001","value":"1.03","spread":"1.3257"}]}]}]},{"type":"PRIMARY","title":"Pain(at 6 Months): Visual Analogue Scale","description":"VISUAL ANALOGUE SCALE:\n\nPain of the participants will be assessed by most widely used and accepted \"visual analogue scale\". It consists of a 10 centimeter line marked at one end with \"no pain\" and at other end with \"worst pain ever\". Participant is asked to indicate where on the line he or she rates the pain on the day of presentation, 1, 4, 12weeks and 6 month of follow-ups. Numerical valve is then given to it simply by measuring length between \"no pain\" to patients mark.\n\nNo pain\\_\\_\\_\\_1 \\_\\_\\_ 2 \\_\\_\\_ 3 \\_\\_\\_ 4 \\_\\_\\_ 5 \\_\\_\\_ 6 \\_\\_\\_ 7 \\_\\_\\_ 8 \\_\\_\\_ 9 \\_\\_\\_ 10 worst pain ever.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.533","spread":"1.907"},{"groupId":"OG001","value":"1.833","spread":"2.0356"}]}]}]},{"type":"PRIMARY","title":"Pain(at 6 Months): Nirschl Staging","description":"NIRSCHL STAGING:\n\nphase1: mild pain with exercise; resolves within 24 hours phase2: pain after exercise; exceeds 48 hours phase3: pain with exercise; does not alter activity phase4: pain with exercise; alters activity phase5: pain with heavy activities of daily living phase6: pain with light activities of daily living; intermittent pain at rest phase7: constant pain at rest; disrupts sleeps\n\nNo pain\\_\\_\\_\\_\\_\\_1 \\_\\_\\_\\_\\_\\_ 2\\_\\_\\_\\_\\_\\_ 3\\_\\_\\_\\_\\_\\_\\_4\\_\\_\\_\\_\\_\\_ 5\\_\\_\\_\\_\\_\\_ 6 \\_\\_\\_\\_\\_ 7 worst pain","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.366","spread":"1.2726"},{"groupId":"OG001","value":"1.233","spread":"1.4308"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Systemic affects of Corticosteroid injection"]}}}